EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Circulating Tumor DNA in Ovarian Cancer: Emerging Roles in Early Detection, Risk Stratification, and Disease Monitoring

Ludovica Pepe, Valeria Zuccalà iD, Walter Giuseppe Giordano iD, Giuseppe Giuffrè, Maurizio Martini iD, Vincenzo Cianci iD, Cristina Mondello, Massimiliano Berretta iD, Stefano Cianci iD, Vincenzo Fiorentino iD, Antonio Ieni iD

Cancers · 21.04.2026 · 18 (8) · 1312

DOI: 10.3390/cancers18081312 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 21.04.2026. Verfasst von Ludovica Pepe und 10 weiteren Autor:innen. Beteiligte Einrichtung: Anatomic Pathology Unit, Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", University of Messina, 98125 Messina, Italy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Early diagnosis of ovarian cancer remains one of the most important unmet needs in gynecologic oncology because survival is strongly stage-dependent and most patients still present with disseminated disease. Conventional non-invasive tools, particularly CA-125, transvaginal ultrasound, and composite triage algorithms, remain clinically useful but are limited by suboptimal sensitivity for stage I disease and by reduced specificity in premenopausal women and in benign inflammatory or endometriosis-associated conditions. Circulating tumor DNA (ctDNA) has therefore emerged as a candidate biomarker capable of extending liquid biopsy beyond conventional serology. In ovarian cancer, however, ctDNA implementation is constrained by low tumor shedding in early-stage disease, marked biologic heterogeneity across histotypes, clonal hematopoiesis-related background noise, and major pre-analytical and analytical sources of variability. This narrative review, informed by structured searches of PubMed, Scopus, and Web of Science, examines the evolving evidence for ctDNA mutations, methylation-based assays, multi-omic platforms, and machine-learning models across three distinct clinical contexts: population screening, preoperative triage of adnexal masses, and post-treatment assessment of molecular residual disease. We also discuss positive predictive value, false-positive harms, health-economic implications, standardization initiatives, and ongoing prospective studies. Overall, current evidence suggests that the most plausible near-term role for liquid biopsy in ovarian cancer is not as a universal stand-alone screening test, but as an integrated component of risk stratification and disease-monitoring frameworks that combine molecular signals with clinicopathologic and imaging data.

Schlagwörter

Stichwörter der Autor:innen

CA-125adnexal massescirculating tumor DNActDNA methylationearly detectionliquid biopsymolecular residual diseasemulti-omic biomarkersovarian cancer

Autor:innen und Institutionen

  • Anatomic Pathology Unit, Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", University of Messina, 98125 Messina, Italy.
  • PhD Program in Translational Molecular Medicine and Surgery, Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, 98125 Messina, Italy.
  • Section of Legal Medicine, Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, 98125 Messina, Italy.
  • Division of Medical Oncology, Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy.
  • Unit of Gynecology and Obstetrics, Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", University of Messina, 98125 Messina, Italy.

ORCID-Profile: Valeria Zuccalà, Walter Giuseppe Giordano, Maurizio Martini, Vincenzo Cianci, Massimiliano Berretta, Stefano Cianci, Vincenzo Fiorentino, Antonio Ieni

Zitieren

APA

Pepe, L., Zuccalà, V., Giordano, W. G., Giuffrè, G., Martini, M., Cianci, V., Mondello, C., Berretta, M., Cianci, S., Fiorentino, V., & Ieni, A. (2026). Circulating Tumor DNA in Ovarian Cancer: Emerging Roles in Early Detection, Risk Stratification, and Disease Monitoring. Cancers, 18(8), 1312. https://doi.org/10.3390/cancers18081312

Vancouver

Pepe L, Zuccalà V, Giordano WG, Giuffrè G, Martini M, Cianci V, et al. Circulating Tumor DNA in Ovarian Cancer: Emerging Roles in Early Detection, Risk Stratification, and Disease Monitoring. Cancers. 2026;18(8):1312. doi:10.3390/cancers18081312

BibTeX
@article{Pepe2026,
  author = {Pepe, Ludovica and Zuccalà, Valeria and Giordano, Walter Giuseppe and Giuffrè, Giuseppe and Martini, Maurizio and Cianci, Vincenzo and Mondello, Cristina and Berretta, Massimiliano and Cianci, Stefano and Fiorentino, Vincenzo and Ieni, Antonio},
  title = {Circulating Tumor DNA in Ovarian Cancer: Emerging Roles in Early Detection, Risk Stratification, and Disease Monitoring},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {8},
  pages = {1312},
  doi = {10.3390/cancers18081312}
}
Kostenlos starten →